N/A N=300 Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments
Opioid Dependence
Primary: Initiation of Treatment for Opioid Dependence — 85; 74; 63; 75 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=83 Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
Schizophrenia
Primary: Medication Adherence — 1.1; 1.9 units on a scale — p==.05
Phase 2 N=49 Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder
Methamphetamine Use Disorder
Primary: Participants Categorized as "Responders" — 11 Participants
Phase 3 N=127 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps
Nasal Polyps · Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) at Week 24 — -0.31; -0.90 Score on a scale — p=0.0140
N/A N=217 Calistar A vs. Calistar S - Comparative Cohort Retrospective Analysis of Single Incision POP Systems
Pelvic Organ Prolapse
Primary: Percentage of Cured Participants According to Barber Criteria — 82.42; 90.48 percentage of cured patients
Phase 1 N=33 Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
HCV Infection
Primary: Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast — 2058.5; 3872.5; 500.1; 601.2 h*ng/mL
N/A N=187 Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation
Type 2 Diabetes Mellitus · Colonoscopy
Primary: Abnormal Glucose Levels After Colonoscopic Preparation — 2; 0; 185 Participants
N/A N=117 Competency-based Approaches to Community Health
Obesity, Childhood
Primary: Change in Child Body Mass Index — 18.1; 18.1; 18.1; 18.2 kg/m^2
N/A N=834 Implementing Evidence Based Treatment of Hypertension
Hypertension
Primary: Percent of Patients Taking Thiazide Diuretics and at BP Goal at Index Visit and 6 Months — 35; 33; 43; 19 Participants
Phase 1 N=3 Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Breast Cancer · Ovarian Cancer · Gynecological Cancer
Primary: Maximum Tolerated Dose (MTD) — NA mg/m2 / mg FD
Phase 2 N=128 Study of DA-9801 to Treat Diabetic Neuropathy
Diabetic Neuropathy
Primary: Change in Clinic Visit Pain Score at the 12 Week Visit Compared to Baseline as Assessed by the 11-point Likert Numerical Rating Scale (NRS) — 6.2; 6.6; 6.6; 6.5 Scores…
N/A N=103 Vectors Post Market: A Study to Assess Pain Relief Using Spinal Cord Stimulation
Chronic Pain
Primary: Change in Overall Pain Intensity on the Visual Analog Scale (0-100) — 45.4 units on a scale
Phase 4 N=27 Statin Therapy in Heart Failure: Potential Mechanisms of Benefit
Heart Failure, Congestive
Primary: LVEF (Left Ventricular Ejection Fraction) — 24; 28; 25; 24 percent ejection fraction — p=0.025
N/A N=234 Changes in Biomarkers Associated With Use of Electronic Cigarettes
Biomarkers
Primary: Change in Biomarker Concentrations: Nicotine Equivalents — 74.9; 79.56 mmol/mg creatinine
N/A N=15 Acupuncture for Sedation in the Intensive Care Unit (ICU)
Delirium · Respiratory Depression · Overmedication
Primary: Success of Blinding — 1; 1 Participants